disease interaction(s) of obesity with prediabetes
Jump to navigation
Jump to search
Introduction
- tirzepatide decreases by 12-20% over 3 years
- tirzepatide decreases Hgb A1c by 0.6% from 5.8% over 3 years
- > 90% of tirzepatide users vs 60% of placebo recipients revert to normoglycemia over 3 years
More general terms
References
- ↑ Jastreboff AM, le Roux CW, Stefanski A et al. Tirzepatide for obesity treatment and diabetes prevention. N Engl J Med 2024 Nov 13; [e-pub] PMID: https://www.ncbi.nlm.nih.gov/pubmed/39536238 https://www.nejm.org/doi/10.1056/NEJMoa2410819